老药新用抗耳念珠菌感染的研究进展

摘要/Abstract

摘要： 多重耐药真菌的出现给抗真菌治疗提出严峻挑战,如耳念珠菌(Candida auris,C. auris)。老药新用,又被称为药物再利用,是指将已获批上市或处于临床研究的药物用于新的适应症或者疾病的治疗。该文回顾了近几年来关于对C. auris有效的老药新用的文章,发现包括抗癌药、镇静止吐药、抗抑郁药、抗高血压药、抗寄生虫药、戒酒药物在内的药物对C. auris也有抑制作用。这些药物大多具有广谱的抗真菌效果,部分药物与传统的抗真菌药物联用时还显示出协同作用,表现出良好的临床抗C. auris感染的应用前景。

关键词: 耳念珠菌, 老药新用, 药物再利用, 耐药, 真菌

中图分类号:

R978.5

薛潇春, 杜明威, 方文捷, 孟慧, 潘炜华, 廖万清. 老药新用抗耳念珠菌感染的研究进展[J]. 中国真菌学杂志, 2023, 18(4): 377-380.

参考文献

[1] WALL G, HERRERA N, LOPEZ-RIBOT J L. Repositionable compounds with antifungal activity against multidrug resistant Candida auris identified in the medicines for Malaria Venture's pathogen box[J]. J Fungi (Basel), 2019, 5(4):92.
[2] SATOH K, MAKIMURA K, HASUMI Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital[J]. Microbiol Immunol, 2009, 53(1):41-44.
[3] 邹玉,陈宗耀,鄂建飞,等.耳念珠菌实验室鉴定方法的研究进展[J].中国真菌学杂志,2022,17(5):414-420,424.
[4] 扈东营,姜伟伟,李航,等.侵袭性念珠菌感染流行病学现状和治疗进展[J].世界临床药物,2020,41(5):323-328.
[5] CHOWDHARY A, VOSS A, MEIS J F. Multidrug-resistant Candida auris: 'new kid on the block' in hospital-associated infections[J]? J Hosp Infect, 2016, 94(3):209-212.
[6] Centers for Disease Control and Prevention. Antifungal susceptibility testing and interpretation[EB/OL].[2023-07-17]. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html.
[7] ZHAN P, YU B, OUYANG L. Drug repurposing: An effective strategy to accelerate contemporary drug discovery[J]. Drug Discov Today, 2022, 27(7):1785-1788.
[8] TURABI K S, DESHMUKH A, PAUL S, et al. Drug repurposing-an emerging strategy in cancer therapeutics[J]. Naunyn Schmiedebergs Arch Pharmacol, 2022, 395(10):1139-1158.
[9] GHOSH D, SEHGAL K, SODNAR B, et al. Drug repurposing for stroke intervention[J]. Drug Discov Today, 2022, 27(7):1974-1982.
[10] PRASANNANJANEYULU V, NENE S, JAIN H, et al. Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis[J]. Cytokine Growth Factor Rev, 2022, 65:12-26.
[11] JAMPILEK J. Drug repurposing to overcome microbial resistance[J]. Drug Discov Today, 2022, 27(7):2028-2041.
[12] KATO Y, NISHIYAMA K, NISHIMURA A, et al. Drug repurposing for the treatment of COVID-19[J]. J Pharmacol Sci, 2022, 149(3):108-114.
[13] LATIFI A. Reviewing the effects of miltefosine and suggesting it for the treatment of coronavirus disease (COVID-19)[J]. Infect Dis (Auckl), 2020, 13.DOI:10.1177/1178633720977488.
[14] VAN HENTEN S, TESFAYE A B, ABDELA S G, et al. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia[J]. PLoS Negl Trop Dis, 2021, 15(5):e0009460.
[15] DE LA PRESA M, IBACH M, BERDAHL J, et al. Anterior scleral and limbal inflammatory necrosis after adjuvant miltefosine for recalcitrant acanthamoeba keratitis[J]. Cornea, 2022, 41(6):775-778.
[16] BARRETO T L, ROSSATO L, DEFREITAS A L D, et al. Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris[J]. Int J Antimicrob Agents, 2020, 56(2):106049.
[17] WU Y, TOTTEN M, MEMON W, et al. In vitro antifungal susceptibility of the emerging multidrug-resistant pathogen Candida auris to miltefosine alone and in combination with amphotericin B[J]. Antimicrob Agents Chemother, 2020, 64(2):e02063-19.
[18] SPADARI C C, VILA T, ROZENTAL S, et al. Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts[J]. Antimicrob Agents Chemother, 2018, 62(8):e00312-18.
[19] GUPTA Y K, GUPTA M, ANEJA S, et al. Current drug therapy of protozoal diarrhoea[J]. Indian J Pediatr, 2004, 71(1):55-58.
[20] LAWUNG R, CHERDTRAKULKIAT R, NABU S, et al. Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant Neisseria gonorrhoeae[J]. EXCLI J, 2018, 17:840-846.DOI:10.17179/excli2018-1602.
[21] BURNETT B P, MITCHELL C M. Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole[J]. Cutis, 2008, 82(4):273-280.
[22] ROLLIN-PINHEIRO R, BORBA-SANTOS L P, DA SILVA XISTO M I D, et al. Identification of promising antifungal drugs against Scedosporium and Lomentospora species after screening of pathogen box library[J]. J Fungi (Basel), 2021,7(10):803.
[23] CHUNG M W, KOMOROWSKI R A, VARMA R R. Suloctidil-induced hepatotoxicity[J]. Gastroenterology, 1988, 95(2):490-491.
[24] DE OLIVEIRA H C, MONTEIRO M C, ROSSI S A, et al. Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen Candida auris[J]. Front Cell Infect Microbiol, 2019, 9:83.DOI:10.3389/fcimb.2019.00083.
[25] ZENG B, LI J, WANG Y, et al. In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus Candida albicans[J]. Oncotarget, 2017, 8(41):69972-69982.
[26] BUTTS A, DIDONE L, KOSELNY K, et al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis[J]. Eukaryot Cell, 2013, 12(2):278-287.
[27] DOUGHTY-SHENTON D, JOSEPH J D, ZHANG J, et al. Pharmacological targeting of the mitochondrial phosphatase PTPMT1[J]. J Pharmacol Exp Ther, 2010, 333(2):584-592.
[28] MAMOUEI Z, ALQARIHI A, SINGH S. Alexidine dihydrochloride has broad-spectrum activities against diverse fungal pathogens[J]. mSphere, 2018, 3(5):e00539-18.
[29] CHENG Y S, ROMA J S, SHEN M, et al. Identification of antifungal compounds against multidrug-resistant Candida auris utilizing a high-throughput drug-repurposing screen[J]. Antimicrob Agents Chemother, 2021, 65(4):e01305-20.
[30] RUIZ-LINARES M, AGUADO-PEREZ B, BACA P,et al. Efficacy of antimicrobial solutions against polymicrobial root canal biofilm[J]. Int Endod J, 2017, 50(1):77-83.
[31] KIM H S, WOO CHANG S, BAEK S H, et al. Antimicrobial effect of alexidine and chlorhexidine against Enterococcus faecalis infection[J]. Int J Oral Sci, 2013, 5(1):26-31.
[32] WANG J, WANG P, DONG C, et al. Mechanisms of ebselen as a therapeutic and its pharmacology applications[J]. Future Med Chem, 2020, 12(23):2141-2160.
[33] AGHAEI GHAREHBOLAGH S, IZADI A, TALEBI M, et al. New weapons to fight a new enemy: A systematic review of drug combinations against the drug-resistant fungus Candida auris[J]. Mycoses, 2021, 64(11):1308-1316.
[34] BILLACK B, SANTORO M, LAU-CAM C. Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: role of the plasma membrane H⁺-ATPase[J]. Microb Drug Resist, 2009, 15(2):77-83.
[35] M S, N R P, CHAKRABORTY A, et al. Proteomic profiling of Deinococcus radiodurans with response to thioredoxin reductase inhibitor and ionizing radiation treatment[J]. J Proteomics,2022,267:104697.DOI:10.1016/j.jprot.2022.104697.
[36] GNAT S, LAGOWSKI D, DYLAG M, et al. In vitro activity of ebselen and diphenyl diselenide alone and in combination with drugs against trichophyton mentagrophytes strains[J]. Pharmaceutics, 2022, 14(6):1158.
[37] AMIN S A, BANERJEE S, SINGH S, et al. First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery[J]. Mol Divers, 2021, 25(3):1827-1838.
[38] GOWRI M, JAYASHREE B, JEYAKANTHAN J, et al. Sertraline as a promising antifungal agent: Inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro[J]. J Appl Microbiol, 2020, 128(2): 426-437.
[39] COSTA SILVA R A, DA SILVA C R, DE ANDRADE NETO J B, et al. In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates[J]. Microbial pathogenesis, 2017, 107: 341-348. DOI:10.1016/j.micpath.2017.04.008.
[40] MEI Y, JIANG T, ZOU Y, et al. FDA approved drug library screening identifies robenidine as a repositionable antifungal[J]. Front Microbiol, 2020, 11:996.DOI:10.3389/fmicb.2020.00996.
[41] PIC E, BURGAIN A, SELLAM A. Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant Candida albicans strains[J]. Medical mycology, 2019, 57(3):387-390.
[42] HAO W, QIAO D, HAN Y, et al. Identification of disulfiram as a potential antifungal drug by screening small molecular libraries[J]. J Infect Chemother, 2021, 27(5):696-701.